… How I treat acute myeloid leukemia in the era of new drugs . Blood . 2020 ; 135 ( 2 ): 85 - 96
… tissue architecture between untreated and perifosine-treated mice, we observed leukocyte …

… between untreated and perifosine-treated mice, we observed … reveal the possibility of new
molecular targets for checkpoint … activation/ inhibition in acute myeloid leukemia. This pathway …

… Perifosine indeed showed superior preclinical tolerability … and ERK1/2 dephosphorylation
in primary acute myeloid cells. … BCR-ABL expressing chronic myeloid leukaemia cell lines was …

… Acute myeloid leukemia (AML) is a highly aggressive hematological malignancy with … new
drugs have been approved by the US Food and Drug Administration (FDA) for the treatment of …

… Primary acute myeloid leukemia (AML) cell populations may … time of first diagnosis, or a new
clone derived either from the … with perifosine in patients with advanced acute leukemias and …

… Acute myeloid leukemia (AML) is a hematopoietic … new drugs that recently received US
Food and Drug Administration approval for AML treatment and promising strategies to treat …

… by their acute or chronic nature, as well as their myeloid or … chronic myeloid leukemia (CML),
acute myeloid leukemia (… of myeloid leukemia, as well as new and more effective …

… on several new targets for pediatric cancer treatment. Among … leukemia (JMML), and in
acute myelogenous leukemia (AML)… assessed as a new approach to treat pediatric tumors. For …

… the importance of testing new or available agents … , Perifosine is also an AKT inhibitor that
exhibits cytotoxicity in AML by decreasing Akt phosphorylation signaling. In addition, perifosine …

… LSC detection, but it also helps to define new LSC-specific treatments and track the benefits
of anti-LSC … Perifosine that inhibits the phosphorylation of Akt negatively, modulates the cell …